GlaxoSmithKline (JOBS), Vernalis PLC Sign up to $200 Million Cancer Deal

Bookmark and Share

Reuters -- GlaxoSmithKline Plc, the world's second-largest drugmaker, has signed a deal potentially worth $200 million with British biotech company Vernalis Plc (VER.L) to boost its early-stage research in cancer.
MORE ON THIS TOPIC